Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

amsacrine

Phase 3Small molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

amsacrine is one of 105 small molecule programs targeting Leukemia. It is currently in Phase 3.

3

Indications

8

Total Trials

1

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

LeukemiaPhase 3

Active, not recruiting

Bone Marrow TransplantationPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Fludara

Vanflyta

Trisenox

Active Comparator

AG-120

Institut de Recherches Internationales Servier

Salvage Chemotherapy

GM-CSF

YY-mAbs Therapeutics

Daunorubicin or Idarubicin

amsacrine

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Lodac

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Stem Cell Transplantation

NCT05807932

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Terminated·UUniversity Hospital, Toulouse·Phase 3·NCT03765541·73 enrolled

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002719·500 enrolled

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Completed·IInstitut Paoli-Calmettes·Phase 1/2·NCT00840684·135 enrolled

Bone Marrow Transplantation2 trials

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00003436·2,000 enrolled

Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia

Unknown status·MMedical Research Council·Phase 3·NCT00002658·2,000 enrolled

Leukemia1 trial

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01324063·160 enrolled

Stem Cell Transplantation1 trial

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Recruiting·HHeinrich-Heine University, Duesseldorf·Phase 1/2·NCT05807932·38 enrolled

Children1 trial

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT01228331·745 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for amsacrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — amsacrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for amsacrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

Related News